





Fig. 1A




2/22

Fig. 1B




3/22

Fig. 1C




4/22



Fig. 1D



5/22



6/22



*Fig. 2*




Fig. 3A

8/22






Fig. 3B



9/22




*Fig. 4*




*Fig. 5A*


10/22



*Fig. 5B*




*Fig. 5C*



*Fig. 5D*





*Fig. 5E*




*Fig. 5F*

11/22

*Fig. 6**Fig. 7*


12/22





RELATIVE COPY NUMBER OF mRNA

□ ENDO CFTR mRNA


▨ AV CFTR mRNA

*Fig. 8A*RELATIVE RATIO OF TRANSGENE/ENDOGENOUS  
DERIVED CFTR mRNA*Fig. 8B*


13/22

*Fig. 9A**Fig. 9B*

14/22




*Fig. 10A*




*Fig. 10B*

15/22




*Fig. 10C*




*Fig. 11A*

16/22




*Fig. 11B*






18/22




*Fig. 12*




*Fig. 13A*

19/22




*Fig. 13B*



*Fig. 13C*

20/22

Fig. 14A



21/22

SAMPLE	AVG RLU/mg	STDEV	FOLD CHANGE
VEHICLE	2.95E+03	9.01E+02	
AAV2 FLAG-LUCIFERASE	1.11E+05	3.77E+04	1.00
MG-132 - 20 $\mu$ M	1.43E+06	1.72E+06	12.90
DOXORUBICIN 6 $\mu$ g/ML	2.10E+07	4.57E+06	189.36
DOXORUBICIN 3 $\mu$ g/ML	6.55E+06	1.15E+05	58.99
DOXORUBICIN 0.6 $\mu$ g/ML	2.55E+05	1.30E+05	2.30
DAUNORUBICIN 6 $\mu$ g/ML	3.17E+08	1.41E+08	2855.65
DAUNORUBICIN 3 $\mu$ g/ML	2.40E+07	2.72E+06	216.42
DAUNORUBICIN 0.6 $\mu$ g/ML	4.09E+05	6.41E+04	3.69
ELLENCE 6 $\mu$ g/ML	1.06E+08	4.85E+07	952.50
ELLENCE 3 $\mu$ g/ML	1.33E+07	2.70E+06	120.13
ELLENCE 0.6 $\mu$ g/ML	3.81E+05	1.78E+05	3.43
IDAMYCIN 6 $\mu$ g/ML	3.87E+04	2.00E+04	0.35
IDAMYCIN 3 $\mu$ g/ML	5.99E+08	1.91E+08	5396.31
IDAMYCIN 0.6 $\mu$ g/ML	5.30E+07	1.48E+07	477.76

*Fig. 14B*

22/22

Fig. 15

